Q-Med acquires Ixion’s entire oxalate project

Through a series of internal transactions Q-Med will become the sole owner of the product development of pharmaceuticals preventing kidney stones. The first step has thereby been taken to seek financing of the very promising projects. In addition to the internal transactions Q-Med is paying a small cash sum to Ixion. “A surplus of oxalate gives recurring kidney stones. These create enormous healthcare costs and not least great personal suffering for both the young and the elderly. Ixion’s technology is very promising and at present leads international development within the area. However, there are no funds for these projects within Q-Med, and therefore we are seeking external backers,” says Bengt Ågerup, President and CEO. Before the internal transactions Q-Med owned 53% of the USA-based company Ixion Biotechnology, Inc., which has been carrying on research into stem cells and the degradation of oxalate. Ixion intends to continue with stem cell research for application within the area of diabetes. Queries should be addressed to: Anne Rhenman, Director Investor Relations and Corporate Communications, Tel: + 46 (0) 70-974 90 15 NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX and all the products within the RESTYLANE family are trademarks that belong to Q-Med. In the US, Q-Med AB´s affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc. Q-Med AB (publ) Seminariegatan 21, SE-752 28 Uppsala, Sweden Corporate identity number 556258-6882 Tel: +46(0) 18-474 90 00 Fax: +46(0) 18-474 90 01 info@q-med.com www.q-med.com